Rahul Khurana, MD
Ophthalmology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 27
- 6 carriers
- Offices
- 3
Offices
3 locations · Northern California Retina Vitreous Associates Medical Group, Inc. · 7 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
27 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Khurana’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
27 of 27 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A87255 · Current
Licensed to practise in California · since 2004 · expires 2028-05-31 · Duke University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,467,099
Medicare paid this office $2,467,099 for 773 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, aflibercept, 1 mg | 222 | $1,627,515 | None |
| Injection, faricimab-svoa, 0.1 mg | 14 | $174,982 | None |
| Injection of drug into eye | 251 | $162,689 | $113 |
| Imaging of retina | 654 | $93,154 | $41 |
| Short return visit (20+ min) | 406 | $79,389 | $87 |
See all 15 services
| Injection, aflibercept, 1 mg | 222 | $1,627,515 | None |
| Injection, faricimab-svoa, 0.1 mg | 14 | $174,982 | None |
| Injection of drug into eye | 251 | $162,689 | $113 |
| Imaging of retina | 654 | $93,154 | $41 |
| Short return visit (20+ min) | 406 | $79,389 | $87 |
| Return visit (30+ min) | 294 | $73,923 | $121 |
| Injection, ranibizumab, 0.1 mg | 15 | $50,512 | None |
| Established patient complete exam of visual system | 315 | $39,548 | $116 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 180 | $36,876 | $174 |
| New patient visit (45+ min) | 112 | $17,209 | $154 |
| Photography of the retina | 230 | $12,141 | $38 |
| New patient complete exam of visual system | 43 | $6,328 | $147 |
| Established patient problem focused exam of visual system | 31 | $3,045 | $90 |
| Extended exam of the back part of the eye with retinal drawing | 44 | $1,100 | $22 |
| 2d ultrasound scan of eye tissue and structures | 12 | $780 | $49 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
773 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 28% · Women 61% · Also on Medicaid 9% · Health risk score 1.21. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 28% · Coronary heart disease 26% · Chronic kidney disease 25% · Atrial fibrillation 20% · Cancer 16% · Heart failure 14% · Depression 12% · COPD 8% · Stroke 8% · Dementia 7%.
The office billed $7,149,598, Medicare allowed $3,137,257 and paid $2,467,099; for 16,173 services of 43 kinds; $1,887,466 of it was for drugs given in the office and $579,633 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 773 | 16,173 | 79 | 1.21 | $7,149,598 | $2,467,099 |
| 2023 | 694 | 13,555 | 79 | 1.22 | $6,708,631 | $2,375,998 |
| 2022 | 670 | 10,521 | 79 | 1.24 | $7,256,014 | $2,655,323 |
| 2021 | 785 | 11,008 | 78 | 1.26 | $7,074,659 | $2,747,476 |
| 2020 | 642 | 9,564 | 79 | 1.45 | $6,118,171 | $2,371,943 |
| 2019 | 733 | 11,042 | 78 | 1.42 | $6,380,131 | $2,481,331 |
| 2018 | 822 | 11,913 | 78 | 1.44 | $6,253,899 | $2,426,006 |
| 2017 | 707 | 10,398 | 78 | 1.44 | $5,065,415 | $2,072,034 |
| 2016 | 670 | 9,935 | 78 | 1.34 | $3,520,756 | $1,732,234 |
| 2015 | 695 | 9,170 | 78 | 1.38 | $3,038,058 | $1,554,947 |
| 2014 | 639 | 7,645 | 78 | 1.32 | $2,499,854 | $1,418,259 |
| 2013 | 696 | 6,754 | 78 | 1.30 | $1,938,424 | $1,146,964 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 18 services
| Injection, aflibercept, 1 mg | 195 | $1,628,209 | None |
| Injection of drug into eye | 232 | $148,019 | $106 |
| Injection, faricimab-svoa, 0.1 mg | 14 | $127,457 | None |
| Injection, ranibizumab, 0.1 mg | 22 | $107,518 | None |
| Imaging of retina | 584 | $81,334 | $39 |
| Return visit (30+ min) | 261 | $48,245 | $114 |
| Established patient problem focused exam of visual system | 273 | $45,935 | $81 |
| Short return visit (20+ min) | 291 | $38,432 | $87 |
| Established patient complete exam of visual system | 268 | $31,870 | $108 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 161 | $28,167 | $139 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 12 | $13,121 | $1,093 |
| New patient visit (45+ min) | 91 | $12,487 | $137 |
| Photography of the retina | 179 | $9,801 | $35 |
| Destruction of leaking blood vessels of retina using laser | 15 | $5,030 | $314 |
| New patient complete exam of visual system | 36 | $4,832 | $134 |
| Compounded drug, not otherwise classified | 14 | $4,496 | None |
| Extended exam of the back part of the eye with retinal drawing | 37 | $874 | $20 |
| 2d ultrasound scan of eye tissue and structures | 12 | $536 | $45 |
2022: 17 services
| Injection, aflibercept, 1 mg | 206 | $1,898,112 | None |
| Injection, ranibizumab, 0.1 mg | 30 | $201,040 | None |
| Injection of drug into eye | 255 | $166,664 | $104 |
| Established patient problem focused exam of visual system | 374 | $90,024 | $84 |
| Imaging of retina | 564 | $82,368 | $39 |
| Return visit (30+ min) | 275 | $54,126 | $108 |
| Established patient complete exam of visual system | 268 | $33,255 | $110 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 161 | $25,253 | $125 |
| Removal of eye fluid (vitreous) between lens and retina | 15 | $10,877 | $640 |
| New patient visit (45+ min) | 71 | $9,450 | $133 |
| Photography of the retina | 142 | $8,018 | $35 |
| Destruction of leaking blood vessels of retina using laser | 13 | $6,976 | $317 |
| Compounded drug, not otherwise classified | 18 | $6,556 | None |
| New patient complete exam of visual system | 19 | $2,450 | $129 |
| Short return visit (20+ min) | 16 | $1,416 | $79 |
| Extended exam of the back part of the eye with retinal drawing | 44 | $1,045 | $22 |
| 2d ultrasound scan of eye tissue and structures | 14 | $629 | $42 |
2021: 18 services
| Injection, aflibercept, 1 mg | 224 | $1,854,885 | None |
| Injection, ranibizumab, 0.1 mg | 37 | $276,628 | None |
| Injection of drug into eye | 292 | $171,300 | $107 |
| Established patient problem focused exam of visual system | 329 | $101,949 | $87 |
| Imaging of retina | 614 | $86,104 | $40 |
| Return visit (30+ min) | 328 | $57,893 | $122 |
| Established patient complete exam of visual system | 364 | $41,178 | $100 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 202 | $29,628 | $121 |
| New patient visit (45+ min) | 135 | $19,680 | $146 |
| Photography of the retina | 306 | $15,350 | $37 |
| Compounded drug, not otherwise classified | 27 | $10,168 | None |
| Destruction of leaking blood vessels of retina using laser | 14 | $7,447 | $298 |
| Photocoagulation treatment to prevent detachment of retina | 12 | $7,071 | $471 |
| Short return visit (20+ min) | 65 | $6,520 | $89 |
| Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | 15 | $4,332 | $255 |
| New patient complete exam of visual system | 20 | $2,954 | $148 |
| Extended exam of the back part of the eye with retinal drawing | 56 | $1,465 | $23 |
| 2d ultrasound scan of eye tissue and structures | 20 | $1,345 | $48 |
2020: 14 services
| Injection, aflibercept, 1 mg | 167 | $1,580,440 | None |
| Injection, ranibizumab, 0.1 mg | 45 | $288,570 | None |
| Injection of drug into eye | 217 | $126,686 | $93 |
| Established patient problem focused exam of visual system | 276 | $112,202 | $85 |
| Imaging of retina | 434 | $67,292 | $40 |
| Established patient complete exam of visual system | 391 | $64,155 | $107 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 165 | $22,671 | $106 |
| New patient visit (45+ min) | 139 | $19,045 | $137 |
| Photography of the retina | 282 | $18,075 | $42 |
| Destruction of leaking blood vessels of retina using laser | 12 | $8,768 | $337 |
| Compounded drug, not otherwise classified | 16 | $7,774 | None |
| 2d ultrasound scan of eye tissue and structures | 22 | $1,591 | $51 |
| Extended exam of the back part of the eye with retinal drawing | 60 | $1,580 | $23 |
| Short return visit (20+ min) | 12 | $1,030 | $74 |
2019: 16 services
| Injection, aflibercept, 1 mg | 163 | $1,298,498 | None |
| Injection, ranibizumab, 0.1 mg | 86 | $625,116 | None |
| Injection of drug into eye | 270 | $137,143 | $92 |
| Established patient problem focused exam of visual system | 351 | $126,928 | $84 |
| Imaging of retina | 486 | $73,337 | $40 |
| Established patient complete exam of visual system | 410 | $67,248 | $108 |
| New patient visit (45+ min) | 164 | $22,879 | $140 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 193 | $22,328 | $92 |
| Photography of the retina | 302 | $21,595 | $47 |
| Compounded drug, not otherwise classified | 43 | $12,637 | None |
| Removal of eye fluid (vitreous) between lens and retina | 14 | $10,898 | $778 |
| Destruction of leaking blood vessels of retina using laser | 16 | $7,301 | $332 |
| Examination of eye by ophthalmoscope with retinal drawing | 67 | $2,734 | $24 |
| 2d ultrasound scan of eye tissue and structures | 24 | $2,319 | $59 |
| Short return visit (20+ min) | 18 | $1,498 | $68 |
| Examination of eye by ophthalmoscope with retinal drawing | 27 | $889 | $27 |
2018: 16 services
| Injection, aflibercept, 1 mg | 108 | $957,250 | None |
| Injection, ranibizumab, 0.1 mg | 105 | $889,064 | None |
| Injection of drug into eye | 287 | $138,516 | $88 |
| Established patient problem focused exam of visual system | 350 | $114,199 | $78 |
| Established patient complete exam of visual system | 511 | $78,229 | $101 |
| Imaging of retina | 533 | $72,654 | $38 |
| New patient visit (45+ min) | 201 | $26,515 | $132 |
| Photography of the retina | 339 | $26,110 | $50 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 232 | $24,833 | $82 |
| Compounded drug, not otherwise classified | 65 | $17,562 | None |
| Destruction of leaking blood vessels of retina using laser | 27 | $12,851 | $313 |
| Photocoagulation treatment to prevent detachment of retina | 11 | $5,189 | $472 |
| Examination of eye by ophthalmoscope with retinal drawing | 76 | $3,124 | $22 |
| Examination of eye by ophthalmoscope with retinal drawing | 51 | $2,063 | $25 |
| Short return visit (20+ min) | 16 | $1,298 | $65 |
| 2d ultrasound scan of eye tissue and structures | 15 | $1,063 | $66 |
2017: 15 services
| Injection, aflibercept, 1 mg | 94 | $863,139 | None |
| Injection, ranibizumab, 0.1 mg | 78 | $684,155 | None |
| Injection of drug into eye | 253 | $123,337 | $88 |
| Established patient problem focused exam of visual system | 306 | $93,601 | $77 |
| Established patient complete exam of visual system | 479 | $77,800 | $99 |
| Imaging of retina | 426 | $62,595 | $38 |
| Photography of the retina | 317 | $28,769 | $62 |
| New patient visit (45+ min) | 151 | $19,065 | $126 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 196 | $18,577 | $71 |
| Compounded drug, not otherwise classified | 89 | $17,902 | None |
| Destruction of leaking blood vessels of retina using laser | 18 | $6,495 | $282 |
| Short return visit (20+ min) | 34 | $2,874 | $67 |
| Examination of eye by ophthalmoscope with retinal drawing | 62 | $2,477 | $22 |
| 2d ultrasound scan of eye tissue and structures | 19 | $2,126 | $82 |
| Examination of eye by ophthalmoscope with retinal drawing | 35 | $1,141 | $24 |
2016: 16 services
| Injection, aflibercept, 1 mg | 83 | $772,129 | None |
| Injection, ranibizumab, 0.1 mg | 44 | $346,345 | None |
| Injection of drug into eye | 258 | $132,818 | $89 |
| Established patient complete exam of visual system | 477 | $87,129 | $102 |
| Established patient problem focused exam of visual system | 276 | $83,541 | $76 |
| Imaging of retina | 418 | $70,146 | $41 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 205 | $55,371 | $98 |
| Compounded drug, not otherwise classified | 140 | $40,003 | None |
| Photography of the retina | 311 | $32,211 | $68 |
| New patient visit (45+ min) | 146 | $18,981 | $130 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 14 | $14,658 | $1,047 |
| Destruction of leaking blood vessels of retina using laser | 17 | $10,221 | $310 |
| Examination of eye by ophthalmoscope with retinal drawing | 55 | $2,475 | $22 |
| 2d ultrasound scan of eye tissue and structures | 12 | $1,571 | $83 |
| Short return visit (20+ min) | 21 | $1,390 | $63 |
| Examination of eye by ophthalmoscope with retinal drawing | 33 | $1,160 | $25 |
2015: 19 services
| Injection, aflibercept, 1 mg | 72 | $625,380 | None |
| Injection, ranibizumab, 0.1 mg | 41 | $348,913 | None |
| Injection of drug into eye | 246 | $114,698 | $93 |
| Established patient complete exam of visual system | 501 | $82,862 | $103 |
| Established patient problem focused exam of visual system | 260 | $68,990 | $77 |
| Imaging of retina | 458 | $64,909 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 218 | $57,194 | $101 |
| Photography of the retina | 298 | $27,396 | $70 |
| New patient visit (45+ min) | 186 | $25,814 | $139 |
| Destruction of leaking blood vessels of retina using laser | 18 | $20,506 | $932 |
| Unclassified biologics | 117 | $19,730 | None |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 11 | $11,955 | $1,087 |
| Compounded Drug, Not Otherwise Classified | 92 | $9,224 | $55 |
| Destruction of growth of retina using a laser | 11 | $7,348 | $490 |
| Photocoagulation treatment to prevent detachment of retina | 11 | $5,867 | $489 |
| Examination of eye by ophthalmoscope with retinal drawing | 83 | $3,670 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 55 | $2,339 | $25 |
| 2d ultrasound scan of eye tissue and structures | 20 | $2,328 | $86 |
| Short return visit (20+ min) | 31 | $2,237 | $62 |
2014: 17 services
| Injection, aflibercept, 1 mg | 63 | $497,864 | None |
| Injection, ranibizumab, 0.1 mg | 62 | $401,567 | None |
| Injection of drug into eye | 222 | $98,315 | $92 |
| Established patient complete exam of visual system | 451 | $91,655 | $106 |
| Imaging of retina | 423 | $53,657 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 211 | $49,737 | $100 |
| Destruction of leaking blood vessels of retina using laser | 30 | $34,081 | $921 |
| Established patient problem focused exam of visual system | 213 | $28,037 | $76 |
| Photography of the retina | 293 | $27,017 | $70 |
| New patient visit (45+ min) | 186 | $26,371 | $142 |
| Unclassified biologics | 119 | $21,609 | None |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 13 | $18,650 | $1,435 |
| Destruction of growth of retina using a laser | 18 | $9,823 | $491 |
| Examination of eye by ophthalmoscope with retinal drawing | 92 | $3,158 | $25 |
| Examination of eye by ophthalmoscope with retinal drawing | 76 | $2,485 | $23 |
| Short return visit (20+ min) | 31 | $2,260 | $66 |
| 2d ultrasound scan of eye tissue and structures | 18 | $2,166 | $87 |
2013: 18 services
| Injection, ranibizumab, 0.1 mg | 54 | $373,822 | None |
| Injection, aflibercept, 1 mg | 39 | $333,187 | None |
| Injection of drug into eye | 197 | $79,504 | $88 |
| Established patient complete exam of visual system | 359 | $49,341 | $99 |
| Imaging of retina | 419 | $49,126 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 204 | $43,803 | $103 |
| Established patient problem focused exam of visual system | 204 | $31,943 | $77 |
| Destruction of leaking blood vessels of retina using laser | 20 | $27,086 | $934 |
| New patient visit (45+ min) | 189 | $27,083 | $143 |
| Photography of the retina | 274 | $22,641 | $69 |
| Unclassified biologics | 110 | $19,635 | None |
| Short return visit (20+ min) | 148 | $12,510 | $60 |
| Destruction of growth of retina using a laser | 20 | $11,227 | $488 |
| 2d ultrasound scan of eye tissue and structures | 18 | $2,330 | $86 |
| Examination of eye by ophthalmoscope with retinal drawing | 80 | $1,994 | $25 |
| Examination of eye by ophthalmoscope with retinal drawing | 48 | $1,348 | $22 |
| Short return visit | 29 | $1,343 | $40 |
| Imaging of optic nerve | 16 | $711 | $42 |
Medicaid work
$378,690 in 2024
Medicaid paid $378,690 for 1,140 billed services this clinician did in 2024, up to 32 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Aflibercept injection | 141 | $210,771 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 378 | $139,909 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 419 | $12,882 |
| Return visit (30+ min) | 113 | $9,515 |
| Short return visit (20+ min) | 77 | $4,857 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 12 | $756 |
| 2024 | 1,140 | 6 | 32 | $378,690 |
| 2023 | 1,383 | 8 | 38 | $477,423 |
| 2022 | 1,293 | 6 | 31 | $530,010 |
| 2021 | 807 | 5 | 23 | $95,984 |
| 2020 | 491 | 5 | 20 | $186,994 |
| 2019 | 931 | 4 | 21 | $182,098 |
| 2018 | 473 | 3 | 20 | $73,786 |
See the largest Medicaid services in earlier years
2023
| Aflibercept injection | 181 | $290,547 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 476 | $161,685 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 497 | $13,809 |
| Return visit (30+ min) | 94 | $4,434 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 64 | $2,721 |
| Injection, bevacizumab, 10 mg | 46 | $2,215 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 13 | $1,604 |
| Short return visit (20+ min) | 12 | $408 |
2022
| Aflibercept injection | 242 | $385,120 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 368 | $123,109 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 512 | $13,327 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 145 | $6,929 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 12 | $1,116 |
| Return visit (30+ min) | 14 | $409 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 374 | $82,133 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 318 | $5,868 |
| Aflibercept injection | 17 | $4,036 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 85 | $3,666 |
| Return visit (30+ min) | 13 | $281 |
2020
| Aflibercept injection | 45 | $103,935 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 192 | $74,271 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 127 | $5,305 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 99 | $1,901 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 28 | $1,581 |
2019
| Aflibercept injection | 40 | $92,713 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 298 | $72,858 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 289 | $8,487 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 304 | $8,040 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 200 | $65,282 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 157 | $5,656 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 116 | $2,848 |
Drugs they prescribed that Part D paid
$9,328
Pharmacies billed $9,328 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 168) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
112 generic and 56 brand-name prescriptions · $9,328 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 45 | $2,785 | $62 |
| Neomycin-Polymyxin-Dexameth | 52 | $559 | $11 |
| Ketorolac Tromethamine | 22 | $463 | $21 |
| Latanoprost | 16 | $69 | $4 |
Year by year
| 2024 | 168 | 67 | 0% (0) | 33% | $9,328 |
| 2023 | 138 | 56 | 0% (0) | 28% | $4,743 |
| 2022 | 166 | 58 | 0% (0) | 25% | $5,524 |
| 2021 | 150 | 59 | None | 40% | $7,763 |
| 2020 | 160 | 55 | None | 53% | $9,212 |
| 2019 | 193 | 72 | 0% (0) | 55% | $10,945 |
| 2018 | 197 | 76 | None | 49% | $16,896 |
| 2017 | 180 | 67 | None | 57% | $11,910 |
| 2016 | 141 | 63 | 0% (0) | 42% | $8,799 |
| 2015 | 129 | 62 | None | 38% | $8,561 |
| 2014 | 120 | 53 | None | None | $29,711 |
| 2013 | 175 | 60 | None | None | $6,719 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Prednisolone Acetate | 38 | $2,064 | $54 |
| Neomycin-Polymyxin-Dexameth | 46 | $609 | $13 |
| Ketorolac Tromethamine | 20 | $522 | $26 |
2022: 4 drugs
| Prednisolone Acetate | 35 | $2,003 | $57 |
| Ketorolac Tromethamine | 36 | $1,448 | $40 |
| Neomycin-Polymyxin-Dexameth | 58 | $786 | $14 |
| Latanoprost | 12 | $78 | $7 |
2021: 4 drugs
| Durezol | 14 | $3,285 | $235 |
| Prednisolone Acetate | 40 | $1,809 | $45 |
| Neomycin-Polymyxin-Dexameth | 60 | $948 | $16 |
| Ketorolac Tromethamine | 24 | $716 | $30 |
2020: 4 drugs
| Durezol | 18 | $4,616 | $256 |
| Prednisolone Acetate | 46 | $1,745 | $38 |
| Ketorolac Tromethamine | 21 | $836 | $40 |
| Neomycin-Polymyxin-Dexameth | 43 | $721 | $17 |
2019: 4 drugs
| Durezol | 22 | $4,949 | $225 |
| Prednisolone Acetate | 57 | $2,141 | $38 |
| Ketorolac Tromethamine | 33 | $1,255 | $38 |
| Neomycin-Polymyxin-Dexameth | 48 | $828 | $17 |
2018: 4 drugs
| Durezol | 19 | $4,557 | $240 |
| Combigan | 11 | $1,882 | $171 |
| Prednisolone Acetate | 31 | $1,065 | $34 |
| Neomycin-Polymyxin-Dexameth | 64 | $900 | $14 |
2017: 4 drugs
| Durezol | 29 | $5,046 | $174 |
| Prednisolone Acetate | 35 | $1,533 | $44 |
| Neomycin-Polymyxin-Dexameth | 51 | $698 | $14 |
| Ketorolac Tromethamine | 14 | $596 | $43 |
2016: 3 drugs
| Durezol | 13 | $2,323 | $179 |
| Neomycin-Polymyxin-Dexameth | 54 | $825 | $15 |
| Prednisolone Acetate | 20 | $797 | $40 |
2015: 3 drugs
| Durezol | 19 | $3,516 | $185 |
| Neomycin-Polymyxin-Dexameth | 61 | $1,022 | $17 |
| Prednisolone Acetate | 17 | $766 | $45 |
2014: 2 drugs
| Prednisolone Acetate | 22 | $1,126 | $51 |
| Neomycin-Polymyxin-Dexameth | 40 | $700 | $17 |
2013: 3 drugs
| Neomycin-Polymyxin-Dexameth | 32 | $615 | $19 |
| Prednisolone Acetate | 30 | $542 | $18 |
| Venlafaxine Hcl Er | 16 | $220 | $14 |
Money from drug and device companies
$10,310 in 2025
| 2025 | 4 | 10 | $9,525 | $10,310 |
| 2024 | 6 | 13 | $14,046 | $14,458 |
| 2023 | 5 | 20 | $25,702 | $27,435 |
| 2022 | 5 | 12 | $18,424 | $18,633 |
| 2021 | 5 | 11 | $4,945 | $5,417 |
| 2020 | 5 | 12 | $13,328 | $13,660 |
| 2019 | 8 | 48 | $56,473 | $60,276 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech | Vabysmo | $4,569 | 2 payments
|
| Genentech USA | None | $3,937 | 4 payments
|
| Abbvie | Ozurdex | $1,700 | 2 payments
|
| Ocular Therapeutix | Dextenza | $104 | 2 payments
|
See all 10 published payments
| Abbvie | Consulting · 2025-11-03 | Ozurdex | $850 |
| Ocular Therapeutix | Meals · 2025-10-17 | Dextenza | $67 |
| Genentech | Meals · 2025-10-16 | None | $189 |
| Genentech | Consulting · 2025-08-27 | Vabysmo | $4,380 |
| Abbvie | Consulting · 2025-08-25 | None | $850 |
| Ocular Therapeutix | Meals · 2025-08-01 | Dextenza | $38 |
| Genentech USA | Travel · 2025-07-31 | None | $38 |
| Genentech USA | Meals · 2025-07-31 | None | $120 |
| Genentech USA | Consulting · 2025-07-31 | None | $3,445 |
| Genentech USA | Travel · 2025-07-31 | None | $334 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $14,458
| Regeneron Pharmaceuticals | Eylea Hd | $6,783 | 5 payments
|
| Abbvie | Ozurdex | $3,896 | 3 payments
|
| Genentech | Vabysmo | $2,520 | 1 payment
|
| Bausch & Lomb Americas | Xipere | $1,022 | 2 payments
|
| Alcon Vision | Clareon | $124 | 1 payment
|
| RxSight | Rxsight Contact Lens | $114 | 1 payment
|
2023: $27,435
| Regeneron Pharmaceuticals | Eylea | $8,615 | 6 payments
|
| Abbvie | None | $8,593 | 8 payments
|
| Regeneron Healthcare Solutions | Eylea | $6,938 | 4 payments
|
| Genentech | Vabysmo | $3,140 | 1 payment
|
| Genentech USA | None | $149 | 1 payment
|
2022: $18,633
| Genentech | Vabysmo | $7,650 | 5 payments
|
| Apellis Pharmaceuticals | None | $4,550 | 1 payment
|
| Bausch & Lomb Americas | Xipere | $3,197 | 3 payments
|
| Regeneron Healthcare Solutions | Eylea | $3,174 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea | $62 | 2 payments
|
2021: $5,417
| Bausch & Lomb a division of Bausch Health US | Xipere | $2,250 | 3 payments
|
| Genentech USA | Lucentis | $1,856 | 5 payments
|
| Aerie Pharmaceuticals | None | $1,125 | 1 payment
|
| Carl Zeiss Meditec USA | None | $125 | 1 payment
|
| Alimera Sciences | Iluvien | $61 | 1 payment
|
2020: $13,660
| Merck Sharp & Dohme | None | $5,790 | 5 payments
|
| Aerie Pharmaceuticals | None | $3,188 | 2 payments
|
| Genentech USA | Lucentis | $3,158 | 3 payments
|
| Bausch & Lomb a division of Bausch Health US | Xipere | $1,500 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea | $24 | 1 payment
|
2019: $60,276
| Allergan | Ozurdex | $22,154 | 21 payments
|
| F. Hoffmann-La Roche AG | Lucentis | $18,583 | 7 payments
|
| Regeneron Healthcare Solutions | Eylea | $15,421 | 10 payments
|
| Aerie Pharmaceuticals | None | $3,375 | 1 payment
|
| Genentech USA | Lucentis | $316 | 3 payments
|
| Genentech | Lucentis | $271 | 3 payments
|
| Hoffmann-La Roche | Non-Covered Product | $107 | 1 payment
|
| Novartis Pharmaceuticals | Beovu | $49 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Va2 Phiii Rhine · 2020 | Their institution | $296,664 |
| Genentech, Inc. · Va2 Phiii Rhine · 2019 | Their institution | $182,732 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2021 | Their institution | $129,179 |
| Genentech, Inc. · Iamd Observational Study · 2023 | Their institution | $120,736 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2024 | Their institution | $119,805 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2022 | Their institution | $105,747 |
| Apellis Pharmaceuticals, Inc. · Study To Compare the Efficacy and Safety of Intravitreal Apl-2 Therapy With Sham Injections in Patients With Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration · 2022 | Their institution | $88,830 |
| Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2023 | Their institution | $77,471 |
| Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2022 | Their institution | $70,964 |
| Genentech, Inc. · A Phase III Study To Investigate Ro7200220 in Patients With Uveitic Macular Edema · 2025 | Their institution | $68,521 |
| Genentech, Inc. · Ph 2 Open Label Extension of Ahtra1 in Ga · 2022 | Their institution | $64,571 |
| Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2020 | Their institution | $62,555 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2023 | Their institution | $59,330 |
| Genentech, Inc. · Iamd Observational Study · 2025 | Their institution | $59,141 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2022 | Their institution | $57,950 |
| Genentech, Inc. · Va2 Phiii Rhine · 2021 | Their institution | $55,975 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2024 | Their institution | $54,234 |
| Genentech, Inc. · Iamd Observational Study · 2024 | Their institution | $51,870 |
| Genentech, Inc. · A Phase III Study To Investigate Ro7200220 in Patients With Uveitic Macular Edema · 2024 | Their institution | $51,299 |
| Genentech, Inc. · Phase 2 of Ro7171009 in Ga · 2021 | Their institution | $41,657 |
| Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2023 | Their institution | $41,127 |
| Genentech, Inc. · Va2 Phiii Rhine · 2022 | Their institution | $38,391 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2022 | Their institution | $33,022 |
| EyePoint Pharmaceuticals US, Inc. · A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), in Subjects With Wet Amd · 2022 | Their institution | $29,638 |
| Genentech, Inc. · Ph 2 Open Label Extension of Ahtra1 in Ga · 2023 | Their institution | $27,219 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2023 | Their institution | $25,663 |
| EyePoint Pharmaceuticals US, Inc. · A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), in Subjects With Wet Amd · 2021 | Their institution | $24,153 |
| Allergan Inc. · Phase 2 - Evaluation of Abicipar Pegol in Patients With Namd 1771-201-008 · 2019 | Their institution | $22,210 |
| Genentech, Inc. · Ph1 Sad of Il33 in Geographic Atrophy · 2022 | Their institution | $22,011 |
| EyePoint Pharmaceuticals US, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of A Fluocinolone Acetonide (Fa) Intravitreal 0.05 Mg Insert (Yutiq 0.05 Mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye · 2022 | Their institution | $19,938 |
| Apellis Pharmaceuticals, Inc. · An Extension Study To Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan (Apl-2) in Subjects With Geographic Atrophy Secondary To Amd · 2025 | Their institution | $15,278 |
| Genentech, Inc. · A Phase III Study To Investigate Ro7200220 in Patients With Uveitic Macular Edema · 2023 | Their institution | $13,518 |
| Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2021 | Their institution | $13,186 |
| Notal Vision, Inc. · Nrich · 2025 | Their institution | $10,020 |
| Genentech, Inc. · Belvedere · 2023 | Their institution | $10,000 |
| Genentech, Inc. · Ph 2 Open Label Extension of Ahtra1 in Ga · 2024 | Their institution | $9,746 |
| Genentech, Inc. · Ph1 Sad of Il33 in Geographic Atrophy · 2021 | Their institution | $8,267 |
| Allergan Inc. · A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-Related Macular Degeneration · 2019 | Their institution | $8,103 |
| ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy · 2025 | Their institution | $8,062 |
| Genentech, Inc. · Safety and Tolerability Study of Ro7171009 in Participants With Geographic Atrophy Ga Secondary To Age-Related Macular Degeneration Amd · 2019 | Their institution | $6,279 |
| Regeneron Pharmaceuticals, Inc. · Health Economics Outcome Research Related To Opthalmology · 2024 | This clinician | $5,325 |
| Genentech, Inc. · Ph1 Sad of Il33 in Geographic Atrophy · 2023 | Their institution | $5,195 |
| EyePoint Pharmaceuticals US, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of A Fluocinolone Acetonide (Fa) Intravitreal 0.05 Mg Insert (Yutiq 0.05 Mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye · 2023 | Their institution | $4,603 |
| F. Hoffmann-La Roche AG · Lucentis Dosing Retreatment · 2020 | This clinician | $4,062 |
| Genentech, Inc. · Ph I of A Htra1 in Ga Secondary To Amd · 2019 | Their institution | $3,772 |
| F. Hoffmann-La Roche AG · Va2 Phiii Yosemite · 2025 | This clinician | $3,163 |
| Boehringer Ingelheim International GmbH · Jade: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding Study To Evaluate the Efficacy and Safety of Bi 1584862 · 2025 | Their institution | $2,984 |
| F. Hoffmann-La Roche AG · Va2 Phiii Yosemite · 2024 | This clinician | $1,938 |
| Alimera Sciences, Inc. · Paladin · 2019 | Their institution | $1,073 |
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2020 | This clinician | $729 |
| Regeneron Pharmaceuticals, Inc. · Health Economics and Outcomes Research (Heor) · 2020 | This clinician | $616 |
| F. Hoffmann-La Roche AG · Il-6 Inhibition With Vamikibart in Patients With Uveitic Macular Edema: Phase 1 Dovetail, and Phase 3 Meerkat and Sandcat Trials · 2024 | This clinician | $600 |
| F. Hoffmann-La Roche AG · Faretina-Dme Real-World Injection Frequency, Visual Acuity and Anatomical Outcomes ?12-Month Follow Up · 2023 | This clinician | $359 |
| ABBVIE INC. · Long-Term Follow-Up Study of Rgx-314 and Fellow Eye Substudy (Rgx-314 Srltfu) · 2025 | Their institution | $339 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Jade: Phase II Trial in Patients With Geographic Atrophy: A Randomized, Double-Masked, Placebo-Controlled, Dose-Finding Study To Evaluate the Efficacy and Safety of Bi 1584862 · 2025 | Their institution | $150 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1912002106
- Licence
- CA A87255California A87255: Current · expires 2028-05-31
- Trained
- Duke University School of Medicine, 2002
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 2485 Hospital Dr, Ste 200, Mountain View, CA, 94040
- NPI first listed
- 2006-09-13
- NPI last updated
- 2013-03-13
This is when the NPI record was last certified, not a medical board exam.